CARD8
Basic information
Region (hg38): 19:48180770-48255946
Links
Phenotypes
GenCC
Source:
- inflammatory bowel disease 30 (Limited), mode of inheritance: Unknown
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Inflammatory bowel disease 30 | AD | Allergy/Immunology/Infectious; Gastrointestinal | The condition can involve sequelae of inflammatory bowel disease, and medical management (eg, with steroids, anti-IL1B monoclonal antibodies) have been described as beneficial | Allergy/Immunology/Infectious; Gastrointestinal | 29408806 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CARD8 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 62 | 10 | 77 | |||
missense | 158 | 174 | ||||
nonsense | 6 | |||||
start loss | 2 | |||||
frameshift | 14 | 15 | ||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 5 | |||||
splice region | 6 | 9 | 15 | |||
non coding | 30 | 40 | ||||
Total | 0 | 0 | 193 | 101 | 26 |
Variants in CARD8
This is a list of pathogenic ClinVar variants found in the CARD8 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
19-48211732-T-C | Uncertain significance (Nov 25, 2023) | |||
19-48211739-C-T | Uncertain significance (Sep 27, 2023) | |||
19-48211740-G-A | Likely benign (Jan 22, 2024) | |||
19-48211768-C-A | Uncertain significance (May 31, 2023) | |||
19-48211775-G-C | Likely benign (Jan 14, 2024) | |||
19-48211778-C-T | Uncertain significance (Dec 01, 2023) | |||
19-48211779-G-A | Benign (Jan 30, 2024) | |||
19-48211779-G-C | Uncertain significance (Jun 07, 2022) | |||
19-48211784-G-A | Likely benign (Sep 14, 2022) | |||
19-48211822-G-T | Uncertain significance (Apr 07, 2023) | |||
19-48211828-T-C | Uncertain significance (Mar 24, 2022) | |||
19-48211831-T-C | Uncertain significance (Feb 09, 2023) | |||
19-48211840-C-T | not specified | Uncertain significance (Jan 02, 2024) | ||
19-48211841-G-A | Uncertain significance (Nov 10, 2023) | |||
19-48211848-T-C | Likely benign (Jul 28, 2023) | |||
19-48211850-C-A | Uncertain significance (Apr 18, 2023) | |||
19-48211856-C-T | not specified | Uncertain significance (Jan 24, 2023) | ||
19-48211864-TC-AA | Uncertain significance (Nov 22, 2022) | |||
19-48211880-T-TAAGA | Uncertain significance (Aug 23, 2022) | |||
19-48211886-C-G | Uncertain significance (Jan 29, 2024) | |||
19-48211896-T-C | Benign (Feb 01, 2024) | |||
19-48211901-G-A | Uncertain significance (Mar 01, 2023) | |||
19-48211908-G-A | Benign (Jan 30, 2024) | |||
19-48211914-C-G | Likely benign (Jun 22, 2022) | |||
19-48211933-C-A | not specified | Uncertain significance (Sep 26, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CARD8 | protein_coding | protein_coding | ENST00000391898 | 11 | 75177 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00000177 | 0.969 | 125632 | 2 | 112 | 125746 | 0.000453 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.923 | 251 | 296 | 0.849 | 0.0000162 | 3520 |
Missense in Polyphen | 84 | 96.456 | 0.87087 | 1225 | ||
Synonymous | 0.178 | 112 | 114 | 0.979 | 0.00000617 | 1019 |
Loss of Function | 2.01 | 13 | 23.5 | 0.552 | 0.00000109 | 287 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000620 | 0.0000615 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000653 | 0.000653 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.000106 | 0.0000967 |
Middle Eastern | 0.000653 | 0.000653 |
South Asian | 0.00301 | 0.00288 |
Other | 0.000168 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Inhibits NF-kappa-B activation. May participate in a regulatory mechanism that coordinates cellular responses controlled by NF-kappa-B transcription factor. May be a component of the inflammasome, a protein complex which also includes PYCARD, NALP2 and CASP1 and whose function would be the activation of proinflammatory caspases.;
- Pathway
- NOD-like receptor signaling pathway - Homo sapiens (human);Nucleotide-binding Oligomerization Domain (NOD) pathway
(Consensus)
Recessive Scores
- pRec
- 0.0634
Intolerance Scores
- loftool
- 0.983
- rvis_EVS
- 1.18
- rvis_percentile_EVS
- 92.79
Haploinsufficiency Scores
- pHI
- 0.0674
- hipred
- N
- hipred_score
- 0.145
- ghis
- 0.420
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.783
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Gene ontology
- Biological process
- apoptotic process;activation of cysteine-type endopeptidase activity involved in apoptotic process;negative regulation of tumor necrosis factor-mediated signaling pathway;negative regulation of lipopolysaccharide-mediated signaling pathway;negative regulation of NF-kappaB transcription factor activity;negative regulation of I-kappaB kinase/NF-kappaB signaling;positive regulation of cysteine-type endopeptidase activity involved in apoptotic process;negative regulation of interleukin-1 beta secretion;positive regulation of interleukin-1 beta secretion;inhibition of cysteine-type endopeptidase activity
- Cellular component
- nucleus;nucleoplasm;cytoplasm;cytosol;protein-containing complex;inflammasome complex;NLRP3 inflammasome complex
- Molecular function
- protein binding;cysteine-type endopeptidase activator activity involved in apoptotic process;NACHT domain binding;protein homodimerization activity;CARD domain binding